Clinical Trials Logo
  1. Home
  2. Impaired Renal Function
  3. NCT04179630

Study of Aldafermin (NGM282) in Participants With Impaired Renal Function

Impaired Renal Function Clinical Trial

Official title:
A Phase 1, Single-center, Open Label, Parallel Group Study to Evaluate the Pharmacokinetics, Safety & Tolerability of a Single Dose of Aldafermin (NGM282) in Subjects With Impaired Renal Function

Clinical Trial Summary

This is a single-center evaluation of Aldafermin (NGM282) in an open-label, single-dose and parallel group study in participants with Impaired Renal Function.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04179630
Study type Interventional
Source NGM Biopharmaceuticals, Inc
Contact
Status Completed
Phase Phase 1
Start date November 8, 2019
Completion date December 14, 2019
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04252430 - RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects Phase 1
Completed NCT01716455 - Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function Phase 1
Completed NCT02431481 - Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011 Phase 1
Completed NCT02087566 - Linezolid Pharmacokinetics In Patients With Impaired Renal Function (PPT6) N/A
Completed NCT00779922 - Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function Phase 2
Completed NCT00784381 - Computer Prescribing System and Impaired Renal Function Phase 3
Completed NCT01507350 - Effects of Obesity Surgery on Renal Function
Active, not recruiting NCT01760031 - Longterm Follow-up After Remote Ischemic Preconditioning for Prevention of Contrast-induced Nephropathy N/A
Completed NCT03776539 - A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02 Phase 1
Completed NCT01035320 - Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment Phase 4
Completed NCT00604357 - CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment Phase 3
Completed NCT02965040 - A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function Phase 1
Completed NCT00981045 - Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function Phase 3
Completed NCT02467478 - Linagliptin's Effect on CD34+ Stem Cells Phase 4
Recruiting NCT04620590 - An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function Phase 4